I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline ...

The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.

By Mariam Sunny and Mrinalika Roy (Reuters) -Novo Nordisk reported promising mid-stage results for its experimental obesity drug amycretin in diabetes patients on Tuesday, sending its Denmark-listed ...

Novo Nordisk announces phase 2 clinical trial results of amycretin in people with type 2 diabetes: Bagsværd, Denmark Thursday, November 27, 2025, 13:00 Hrs [IST] Novo Nordisk, a ...

In a phase II study, Novo Nordisk A/S’s amycretin reduced the weight of type 2 diabetes patients by 14.5% in 36 weeks, a statistically significant loss. The results also produced reduced hemoglobin ...

Shares of Novo Nordisk NVO were up 4.7% yesterday, after the company announced positive data from a phase II study evaluating its investigational pipeline candidate, amycretin, in people with type 2 ...